著者

Emi Takashita Hiroko Morita Shiho Nagata Masayuki Shirakura Seiichiro Fujisaki Hideka Miura Ikuyo Takayama Tomoko Arita Yasushi Suzuki Masaoki Yamaoka Taichiro Tanikawa Ryota Tsunekuni Junki Mine Saki Sakuma Yuko Uchida Akihiro Shibata Mari Iwanaka Noriko Kishida Kazuya Nakamura Tsutomu Kageyama Shinji Watanabe Hideki Hasegawa The Influenza Virus Surveillance Group of Japan

出版者

National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee

雑誌

Japanese Journal of Infectious Diseases (ISSN:13446304)

巻号頁・発行日

pp.JJID.2021.751, (Released:2021-12-28)

参考文献数

15

被引用文献数

1

---

Circulation of avian influenza A viruses in poultry is a public health concern because these viruses may cause severe disease in humans and have the potential to become more transmissible among humans. Monitoring the susceptibility of these viruses to antivirals is important for influenza pandemic preparedness. However, information about their antiviral susceptibility is limited. Here, we determined the susceptibilities of avian influenza A(H5N1), A(H5N2), A(H5N8), A(H7N7), A(H7N9), A(H9N1), and A(H9N2) viruses isolated in Japan to the antivirals approved for use there: the M2 inhibitor amantadine; the neuraminidase inhibitors oseltamivir, peramivir, zanamivir, and laninamivir; and the RNA polymerase inhibitors baloxavir and favipiravir. Genotypic methods that detect amino acid substitutions associated with antiviral resistance and phenotypic methods that assess viral susceptibility to drugs revealed that these avian influenza A viruses are susceptible to neuraminidase inhibitors and RNA polymerase inhibitors. These results suggest that the neuraminidase inhibitors and the RNA polymerase inhibitors currently approved in Japan could be a treatment option against influenza A virus infections in humans.